Methanogen

Methanogens are a specialized group of anaerobic archaea that generate methane as a metabolic byproduct of hydrogen consumption [3]. In the human gastrointestinal tract, the primary species is Methanobrevibacter smithii, which plays a significant role in metabolic efficiency and gut motility [3]. Excessive colonization, known as Intestinal Methanogen Overgrowth (IMO), is strongly associated with constipation-predominant irritable bowel syndrome (IBS-C) and may contribute to obesity by increasing caloric harvest from the diet [2]. Therapeutic strategies target these organisms through specialized antibiotics like rifaximin or neomycin, and more specifically through HMG-CoA reductase inhibitors like lovastatin, which disrupt the unique isoprenoid-based cell membranes of archaea [1]. Reducing methane production is a key clinical goal for improving gastrointestinal transit time and alleviating symptoms of bloating and constipation [2]. In agricultural contexts, compounds like 3-nitrooxypropanol are used to inhibit the enzyme methyl-coenzyme M reductase to reduce environmental methane emissions [4]. Sources: [1] Gottlieb et al. (2016) Aliment Pharmacol Ther; [2] Pimentel et al. (2020) Am J Gastroenterol; [3] Gaci et al. (2014) World J Gastroenterol; [4] Hristov et al. (2015) PNAS.

Other names

Methane-producing archaebacteriaMethanogenic archaeaIntestinal methanogensMethanobrevibacter smithii

Inhibition of HMG-CoA reductase to disrupt archaeal cell membrane synthesis; inhibition of methyl-coenzyme M reductase (MCR) to block methanogenesis; broad-spectrum antimicrobial activity.